Pfizer Inc. (PFE) — closed signal from September 11, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on December 10, 2025.
Predicted vs. what happened
What happened
Reached its target in 20 days.
The thesis — published September 11, 2025
Pfizer may be set for a short-term rebound after a sharp slide. Headlines about tariffs and limits on drug ads could weigh on the group, but investor interest is still decent. Because the trend is not yet healthy, we plan to start near the lower price range and add only if shares climb and hold above 26, aiming for a careful 0-3 month recovery in a sturdy, defensively minded large company.
Primary drivers
- The stock dropped sharply, so a short-term rebound could be on the table soon
- Investor interest remains solid, and shares look reasonably priced today
- Headlines on drug pricing and tariffs could limit how far shares can climb
- Wait for proof the downtrend is easing to avoid buying too early and getting stuck
How it played out
PFE: target reached in 20 days
Lyra published PFE at $24.2 on 2025-09-11, looking for 11% short-term growth toward $26.4. The thesis pointed to a possible rebound after a sharp slide, decent investor interest, a reasonable price, and caution around drug pricing and tariff headlines. It also said the trend was not yet healthy.
Inside the window, PFE reached a peak of $27.21 on 2025-10-03. That was a 12.4% gain, and the target was reached in 20 days. The stock ended the window at $25.78. The thesis played out.
What happened during the window
On 2025-09-30, Pfizer and the Trump administration announced a drug pricing agreement that included discounted sales through TrumpRx.gov and a tariff reprieve. On 2025-10-31, Axios reported that Pfizer sued to block Novo Nordisk's competing bid for Metsera.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.